Vivek Ramaswamy, the hedge fund manager turned biotech entrepreneur, was so confident he could make money from pharma drug castoffs, he named his new venture Roivant Sciences — the “Roi” being shorthand for return on investment.

Turns out, Ramaswamy meant his return on investment. Outside investors in Ramaswamy’s publicly traded “Vant” spinoffs are still waiting for their share.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’d love to read Feuerstein’s articles and do whenever they make it into the Globe. His is an important beat and he makes it accessible and exciting, particularly for someone who’s daughter is in the business. But I’m retired and living on a fixed budget and can’t pay ever columnist I like to read. Subscriptions to the Globe, Times, and WSJ will have to suffice. I’ll buy Firestone tires because I need to get around but not Feuerstein articles on a piecemeal basis. Can we make a deal?

  • This is hilarious, they have no idea what they arw doing. He hired his brother, straight out of med school and gave him a Vice President position. Now Chief Business Officer.

    Do they not get biotech news in Japan?

  • I noticed this guy back in 2016 and his wannabe viagra tactics…as a research scientist it blows my mind how supposed investors are falling for this. Anyhows, I’m going to go back to making therapeutics now #lesshypejustdata

  • What the heck, how is this guy still a thing? If sumitomo did an ounce of due diligence, they would know to stay away from his smoke and mirrors tricks. 3 billion? Also just for “his” controlling stake? If anybody wants to give up their controlling stake in anything, you have to be extra careful. These BD guys at Sumitomo need to get their heads checked. They also need more money cause they’re cash position an’t 3b big. Truly pisses me off seeing a Japanese company getting the short end of the stick.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy